Loading...
Internationally Recognized Certificates of Compliance (IRCC)
  |  
| 
last updated: 21 Sep 2019
General Information
ABSCH-IRCC-IN-247889-1
- Competent National Authority: | ABSCH-CNA-IN-202013-2
Competent National Authority:
National Biodiversity Authority ()
5th Floor, TICEL Biopark, CSIR Road, Taramani
Chennai, Tamilnadu
600 113, India
Phone: +91 44 2254 2777,
Fax: +91 44 2254 1200,
Details of the permit or its equivalent
India/NBA/Appl/9/1605
Application in Form-III for seeking approval for the invention on "Therapeutic compositions from the Brevinin-1 family of peptides and uses thereof" for obtaining IP Rights in India, France, Japan, Germany, Spain, United Kingdom, Switzerland, Italy, United States of America, Australia, Canada, China and Republic of Korea

Indian Patent Application Number: 201641020429


01 Jun 2018
Prior Informed Consent (PIC) Information
Yes
- Competent National Authority: | ABSCH-CNA-IN-202013-2
Competent National Authority:
National Biodiversity Authority ()
5th Floor, TICEL Biopark, CSIR Road, Taramani
Chennai, Tamilnadu
600 113, India
Phone: +91 44 2254 2777,
Fax: +91 44 2254 1200,
Confidential information
Confidential information
Mutually Agreed Terms (MAT) Information
Yes
1. The user shall notify the NBA within 60 days from the date of grant of IPR.
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be 0.2% on the annual gross ex-factory sale minus government taxes. 
3. The user shall inform the NBA about any commercialization made on the IP Rights granted.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon.   



Subject-matter or genetic resource(s)
For obtaining IP Rights on the Invention on “Therapeutic compositions from the Brevinin-1 family of peptides and uses thereof" for obtaining IP Rights in India, France, Japan, Germany, Spain, United Kingdom, Switzerland, Italy, United States of America, Australia, Canada, China, and Republic of Korea.

Biological Resources:

Fungoid frog- Hydrophylax bahuvistara (skin secretion)

Confidential information
Information on the utilization of the genetic resource(s)
  • Commercial
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 3.0% of the fee received (in any form including the license / assignee fee) and 2.0% of the royalty amount received annually from the assignee/licensee. 

2. In case the user assigns or transfers the IPR in whole or in part to any person, whether voluntarily or involuntarily, the user undertakes to attach this agreement as an appendix to the assignment instrument, which shall be binding upon such person.   


Additional Information
Amendment history
Unique identifier Status Date
ABSCH-IRCC-IN-247889-1
REVOKED OLD VERSION PUBLISHED DELETED
Sujata Arora (sujata@nic.in)
21 Sep 2019 16:02
on 21 Sep 2019 16:02